Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

被引：0
|
作者：
Tomokazu Kishiki
Hiroaki Ohnishi
Tadahiko Masaki
Kouki Ohtsuka
Yasuo Ohkura
Jyunji Furuse
Takashi Watanabe
Masanori Sugiyama
机构：
[1] Kyorin University School of Medicine,Department of Surgery
[2] Kyorin University School of Medicine,Department of Laboratory Medicine
[3] Kyorin University School of Medicine,Department of Pathology
[4] Kyorin University School of Medicine,Department of Medical Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 73卷
关键词：
Colorectal cancer; PTEN; MET; Anti-EGFR therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：749 / 757
页数：8
相关论文
共 50 条
  • [41] Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer-PARADIGM Shift
    Robinson, Hannah R.
    Lieu, Christopher H.
    JAMA ONCOLOGY, 2023, 9 (06) : 767 - 769
  • [42] Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
    Chen, Yu
    Shi, Yi
    Lin, Jing
    Ye, Yun-bin
    Wang, Xiao-jie
    Chen, Gang
    Guo, Zeng-qing
    MEDICINE, 2015, 94 (40)
  • [43] Identifying prognostic subgroups for outcomes in wild-type RAS metastatic colorectal cancer (mCRC) treated with anti-EGFR drugs
    Vladimirova, L.
    Kit, O.
    Abramova, N.
    Storozhakova, A.
    Popova, I.
    Tikhanovskaya, N.
    Ezhova, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy?
    Airoldi, Marco
    Bartolini, Michela
    Fazio, Roberta
    Farinatti, Sara
    Dapra, Valentina
    Santoro, Armando
    Puccini, Alberto
    CURRENT ONCOLOGY REPORTS, 2024, 26 (11) : 1489 - 1501
  • [45] KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
    Soulieres, D.
    Greer, W.
    Magliocco, Anthony M.
    Huntsman, D.
    Young, S.
    Tsao, M-S.
    Kamel-Reid, S.
    CURRENT ONCOLOGY, 2010, 17 : S31 - S40
  • [46] Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
    Yang, Jiao
    Li, Shuting
    Wang, Biyuan
    Wu, Yinying
    Chen, Zheling
    Lv, Meng
    Lin, Yayun
    Yang, Jin
    TUMOR BIOLOGY, 2016, 37 (09) : 11645 - 11655
  • [47] Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
    Wang, Chongkai
    Sandhu, Jaideep
    Fakih, Marwan
    ONCOLOGIST, 2022, 27 (02): : 104 - 109
  • [48] The efficacy of anti-EGFR therapy across different lines of treatment in RAS wild-type left-sided metastatic colorectal cancer.
    Akewanlop, Charuwan
    Korphaisarn, Krittiya
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 86 - 86
  • [49] Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
    Martins, Marta
    Mansinho, Andre
    Cruz-Duarte, Raquel
    Martins, Soraia Lobo
    Costa, Luis
    TARGETED THERAPY OF COLORECTAL CANCER SUBTYPES, 2018, 1110 : 113 - 131
  • [50] Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): Continuation of anti-EGFR therapy while switching chemotherapy regimen.
    Vladimirova, Liubov Yu
    Abramova, Natalya A.
    Kit, Oleg Ivanovich
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345